nodes	percent_of_prediction	percent_of_DWPC	metapath
Methylphenidate—CYP2D6—Bicalutamide—prostate cancer	0.094	0.504	CbGbCtD
Methylphenidate—CYP2D6—Abiraterone—prostate cancer	0.0779	0.418	CbGbCtD
Methylphenidate—CYP2D6—Doxorubicin—prostate cancer	0.0144	0.0773	CbGbCtD
Methylphenidate—SLC6A2—NRF2 pathway—GSTP1—prostate cancer	0.000241	0.00153	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—NGFR—prostate cancer	0.00024	0.00153	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmission across Chemical Synapses—ACHE—prostate cancer	0.00024	0.00152	CbGpPWpGaD
Methylphenidate—CYP2D6—Melatonin metabolism and effects—GSK3B—prostate cancer	0.000239	0.00152	CbGpPWpGaD
Methylphenidate—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP3A4—prostate cancer	0.000238	0.00152	CbGpPWpGaD
Methylphenidate—SLC6A3—NRF2 pathway—EGR1—prostate cancer	0.000238	0.00151	CbGpPWpGaD
Methylphenidate—SLC6A3—NRF2 pathway—GGT1—prostate cancer	0.000238	0.00151	CbGpPWpGaD
Methylphenidate—CYP2D6—Phase 1 - Functionalization of compounds—CYP2A6—prostate cancer	0.000236	0.0015	CbGpPWpGaD
Methylphenidate—CYP2D6—Oxidation by Cytochrome P450—CYP3A4—prostate cancer	0.000235	0.0015	CbGpPWpGaD
Methylphenidate—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP1B1—prostate cancer	0.000234	0.00149	CbGpPWpGaD
Methylphenidate—CYP2D6—Biological oxidations—CYP7B1—prostate cancer	0.000232	0.00148	CbGpPWpGaD
Methylphenidate—CYP2D6—Oxidation by Cytochrome P450—CYP1B1—prostate cancer	0.000231	0.00147	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmission across Chemical Synapses—PRKACB—prostate cancer	0.000229	0.00146	CbGpPWpGaD
Methylphenidate—SLC6A3—SLC-mediated transmembrane transport—SLC22A1—prostate cancer	0.000229	0.00146	CbGpPWpGaD
Methylphenidate—CYP2D6—Metapathway biotransformation—CYP7B1—prostate cancer	0.000229	0.00146	CbGpPWpGaD
Methylphenidate—SLC6A3—Neuronal System—PLCB2—prostate cancer	0.000227	0.00144	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—NR3C1—prostate cancer	0.000226	0.00144	CbGpPWpGaD
Methylphenidate—CYP2D6—Biological oxidations—SULT1E1—prostate cancer	0.000226	0.00144	CbGpPWpGaD
Methylphenidate—CYP2D6—Phase 1 - Functionalization of compounds—CYP17A1—prostate cancer	0.000226	0.00144	CbGpPWpGaD
Methylphenidate—CYP2D6—Cytochrome P450 - arranged by substrate type—NCOA1—prostate cancer	0.000224	0.00142	CbGpPWpGaD
Methylphenidate—SLC6A3—NRF2 pathway—RXRA—prostate cancer	0.000223	0.00142	CbGpPWpGaD
Methylphenidate—CYP2D6—Metapathway biotransformation—SULT1E1—prostate cancer	0.000223	0.00142	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—SLC39A1—prostate cancer	0.000222	0.00141	CbGpPWpGaD
Methylphenidate—SLC6A2—NRF2 pathway—GSTM1—prostate cancer	0.000222	0.00141	CbGpPWpGaD
Methylphenidate—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP19A1—prostate cancer	0.00022	0.0014	CbGpPWpGaD
Methylphenidate—CYP2D6—Oxidation by Cytochrome P450—CYP19A1—prostate cancer	0.000217	0.00138	CbGpPWpGaD
Methylphenidate—SLC6A3—Neuronal System—SLC22A1—prostate cancer	0.000217	0.00138	CbGpPWpGaD
Methylphenidate—CYP2D6—Phase 1 - Functionalization of compounds—NCOA2—prostate cancer	0.000215	0.00137	CbGpPWpGaD
Methylphenidate—SLC6A3—NRF2 pathway—TGFBR2—prostate cancer	0.000214	0.00136	CbGpPWpGaD
Methylphenidate—SLC6A3—NRF2 pathway—GSTP1—prostate cancer	0.000214	0.00136	CbGpPWpGaD
Methylphenidate—CYP2D6—Cytochrome P450 - arranged by substrate type—RXRA—prostate cancer	0.000213	0.00135	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—SIRT1—prostate cancer	0.000208	0.00132	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—HIF1A—prostate cancer	0.000206	0.00131	CbGpPWpGaD
Methylphenidate—SLC6A3—Neuronal System—GNG5—prostate cancer	0.000206	0.00131	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—CYP7B1—prostate cancer	0.000204	0.0013	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—TYMS—prostate cancer	0.000202	0.00128	CbGpPWpGaD
Methylphenidate—CYP2D6—Phase 1 - Functionalization of compounds—CYP2E1—prostate cancer	0.0002	0.00128	CbGpPWpGaD
Methylphenidate—CYP2D6—Biological oxidations—CYP3A5—prostate cancer	0.000199	0.00127	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—SLC26A4—prostate cancer	0.000199	0.00127	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—SLC12A2—prostate cancer	0.000199	0.00127	CbGpPWpGaD
Methylphenidate—SLC6A3—NRF2 pathway—GSTM1—prostate cancer	0.000196	0.00125	CbGpPWpGaD
Methylphenidate—CYP2D6—Metapathway biotransformation—CYP3A5—prostate cancer	0.000196	0.00125	CbGpPWpGaD
Methylphenidate—CYP2D6—Phase 1 - Functionalization of compounds—CYP3A4—prostate cancer	0.000193	0.00123	CbGpPWpGaD
Methylphenidate—CYP2D6—Biological oxidations—GSTA3—prostate cancer	0.000192	0.00122	CbGpPWpGaD
Methylphenidate—CYP2D6—Phase 1 - Functionalization of compounds—CYP1B1—prostate cancer	0.00019	0.00121	CbGpPWpGaD
Methylphenidate—CYP2D6—Metapathway biotransformation—GSTA3—prostate cancer	0.00019	0.00121	CbGpPWpGaD
Methylphenidate—SLC6A2—SLC-mediated transmembrane transport—SLC5A5—prostate cancer	0.000189	0.0012	CbGpPWpGaD
Methylphenidate—SLC6A3—Neuronal System—ACHE—prostate cancer	0.000184	0.00117	CbGpPWpGaD
Methylphenidate—CYP2D6—Phase 1 - Functionalization of compounds—NCOA1—prostate cancer	0.000181	0.00115	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—CYP7B1—prostate cancer	0.000181	0.00115	CbGpPWpGaD
Methylphenidate—CYP2D6—Phase 1 - Functionalization of compounds—CYP19A1—prostate cancer	0.000179	0.00114	CbGpPWpGaD
Methylphenidate—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP1A1—prostate cancer	0.000178	0.00113	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—SLC12A2—prostate cancer	0.000176	0.00112	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—SLC26A4—prostate cancer	0.000176	0.00112	CbGpPWpGaD
Methylphenidate—CYP2D6—Biological oxidations—TBXAS1—prostate cancer	0.000176	0.00112	CbGpPWpGaD
Methylphenidate—CYP2D6—Biological oxidations—GSTA4—prostate cancer	0.000176	0.00112	CbGpPWpGaD
Methylphenidate—SLC6A3—Neuronal System—PRKACB—prostate cancer	0.000176	0.00112	CbGpPWpGaD
Methylphenidate—CYP2D6—Oxidation by Cytochrome P450—CYP1A1—prostate cancer	0.000175	0.00112	CbGpPWpGaD
Methylphenidate—CYP2D6—Metapathway biotransformation—GSTA4—prostate cancer	0.000173	0.0011	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—PPARA—prostate cancer	0.000173	0.0011	CbGpPWpGaD
Methylphenidate—CYP2D6—Phase 1 - Functionalization of compounds—RXRA—prostate cancer	0.000172	0.0011	CbGpPWpGaD
Methylphenidate—CYP2D6—Biological oxidations—GSTA2—prostate cancer	0.000171	0.00109	CbGpPWpGaD
Methylphenidate—CYP2D6—Biological oxidations—SULT1A1—prostate cancer	0.000169	0.00108	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—CREBBP—prostate cancer	0.000168	0.00107	CbGpPWpGaD
Methylphenidate—SLC6A3—SLC-mediated transmembrane transport—SLC5A5—prostate cancer	0.000167	0.00106	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmission across Chemical Synapses—COMT—prostate cancer	0.000167	0.00106	CbGpPWpGaD
Methylphenidate—CYP2D6—Metapathway biotransformation—SULT1A1—prostate cancer	0.000167	0.00106	CbGpPWpGaD
Methylphenidate—CYP2D6—Biological oxidations—GSTA1—prostate cancer	0.000165	0.00105	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—LEP—prostate cancer	0.000164	0.00104	CbGpPWpGaD
Methylphenidate—CYP2D6—Biological oxidations—NAT2—prostate cancer	0.000163	0.00104	CbGpPWpGaD
Methylphenidate—CYP2D6—Biological oxidations—GSTO1—prostate cancer	0.000163	0.00104	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—SLC22A3—prostate cancer	0.000161	0.00103	CbGpPWpGaD
Methylphenidate—CYP2D6—Metapathway biotransformation—NAT2—prostate cancer	0.000161	0.00103	CbGpPWpGaD
Methylphenidate—CYP2D6—Metapathway biotransformation—GSTO1—prostate cancer	0.000161	0.00103	CbGpPWpGaD
Methylphenidate—CYP2D6—Biological oxidations—CYP2C18—prostate cancer	0.000157	0.000997	CbGpPWpGaD
Methylphenidate—CYP2D6—Metapathway biotransformation—CYP2C18—prostate cancer	0.000154	0.000983	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—ABCG5—prostate cancer	0.000149	0.000947	CbGpPWpGaD
Methylphenidate—CYP2D6—Biological oxidations—SULT2A1—prostate cancer	0.000146	0.000926	CbGpPWpGaD
Methylphenidate—CYP2D6—Phase 1 - Functionalization of compounds—CYP1A1—prostate cancer	0.000144	0.000916	CbGpPWpGaD
Methylphenidate—CYP2D6—Metapathway biotransformation—SULT2A1—prostate cancer	0.000144	0.000914	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—SLC22A3—prostate cancer	0.000143	0.000909	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—GSK3B—prostate cancer	0.000142	0.000905	CbGpPWpGaD
Methylphenidate—CYP2D6—Metapathway biotransformation—GPX3—prostate cancer	0.000137	0.000872	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—CXCL8—prostate cancer	0.000134	0.000851	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—ABCG5—prostate cancer	0.000132	0.000839	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—SLC22A1—prostate cancer	0.000131	0.000836	CbGpPWpGaD
Methylphenidate—CYP2D6—Biological oxidations—HPGDS—prostate cancer	0.000131	0.000831	CbGpPWpGaD
Methylphenidate—CYP2D6—Biological oxidations—CYP2C19—prostate cancer	0.00013	0.000826	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—SERPINE1—prostate cancer	0.000129	0.00082	CbGpPWpGaD
Methylphenidate—CYP2D6—Metapathway biotransformation—CYP2C19—prostate cancer	0.000128	0.000814	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—CASP3—prostate cancer	0.000128	0.000814	CbGpPWpGaD
Methylphenidate—SLC6A3—Neuronal System—COMT—prostate cancer	0.000128	0.000814	CbGpPWpGaD
Methylphenidate—CYP2D6—Biological oxidations—GSTT1—prostate cancer	0.000127	0.000806	CbGpPWpGaD
Methylphenidate—CYP2D6—Biological oxidations—CYP2A6—prostate cancer	0.000125	0.000797	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—GNG5—prostate cancer	0.000125	0.000796	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—CTNNB1—prostate cancer	0.000123	0.000785	CbGpPWpGaD
Methylphenidate—CYP2D6—Metapathway biotransformation—AKR1C3—prostate cancer	0.00012	0.000764	CbGpPWpGaD
Methylphenidate—CYP2D6—Biological oxidations—CYP17A1—prostate cancer	0.00012	0.000763	CbGpPWpGaD
Methylphenidate—CYP2D6—Metapathway biotransformation—CYP17A1—prostate cancer	0.000118	0.000752	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—SLC22A1—prostate cancer	0.000116	0.000741	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—EP300—prostate cancer	0.000115	0.000729	CbGpPWpGaD
Methylphenidate—CYP2D6—Biological oxidations—NCOA2—prostate cancer	0.000114	0.000727	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—GNG5—prostate cancer	0.000111	0.000705	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—VEGFA—prostate cancer	0.000109	0.000691	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—PRKACB—prostate cancer	0.000107	0.000678	CbGpPWpGaD
Methylphenidate—CYP2D6—Biological oxidations—CYP2E1—prostate cancer	0.000106	0.000677	CbGpPWpGaD
Methylphenidate—SLC6A4—NRF2 pathway—TGFB1—prostate cancer	0.000105	0.000669	CbGpPWpGaD
Methylphenidate—CYP2D6—Metapathway biotransformation—CYP2E1—prostate cancer	0.000105	0.000668	CbGpPWpGaD
Methylphenidate—CYP2D6—Biological oxidations—CYP3A4—prostate cancer	0.000103	0.000653	CbGpPWpGaD
Methylphenidate—CYP2D6—Metapathway biotransformation—CYP3A4—prostate cancer	0.000101	0.000644	CbGpPWpGaD
Methylphenidate—CYP2D6—Biological oxidations—CYP1B1—prostate cancer	0.000101	0.000642	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—NCOA2—prostate cancer	0.000101	0.00064	CbGpPWpGaD
Methylphenidate—CYP2D6—Metapathway biotransformation—CYP1B1—prostate cancer	9.96e-05	0.000633	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—PTEN—prostate cancer	9.82e-05	0.000624	CbGpPWpGaD
Methylphenidate—CYP2D6—Biological oxidations—GGT1—prostate cancer	9.78e-05	0.000622	CbGpPWpGaD
Methylphenidate—CYP2D6—Biological oxidations—NCOA1—prostate cancer	9.63e-05	0.000613	CbGpPWpGaD
Methylphenidate—Paraesthesia—Docetaxel—prostate cancer	9.63e-05	0.000147	CcSEcCtD
Methylphenidate—Erythema multiforme—Epirubicin—prostate cancer	9.63e-05	0.000147	CcSEcCtD
Methylphenidate—Anxiety—Prednisone—prostate cancer	9.61e-05	0.000146	CcSEcCtD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—SLC5A5—prostate cancer	9.59e-05	0.00061	CbGpPWpGaD
Methylphenidate—Bradycardia—Doxorubicin—prostate cancer	9.59e-05	0.000146	CcSEcCtD
Methylphenidate—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	9.58e-05	0.000146	CcSEcCtD
Methylphenidate—Dyspnoea—Docetaxel—prostate cancer	9.56e-05	0.000146	CcSEcCtD
Methylphenidate—Somnolence—Docetaxel—prostate cancer	9.53e-05	0.000145	CcSEcCtD
Methylphenidate—Discomfort—Prednisone—prostate cancer	9.53e-05	0.000145	CcSEcCtD
Methylphenidate—Eye disorder—Epirubicin—prostate cancer	9.51e-05	0.000145	CcSEcCtD
Methylphenidate—Hypersensitivity—Etoposide—prostate cancer	9.51e-05	0.000145	CcSEcCtD
Methylphenidate—CYP2D6—Biological oxidations—CYP19A1—prostate cancer	9.49e-05	0.000604	CbGpPWpGaD
Methylphenidate—Haemoglobin—Doxorubicin—prostate cancer	9.47e-05	0.000144	CcSEcCtD
Methylphenidate—Musculoskeletal discomfort—Capecitabine—prostate cancer	9.46e-05	0.000144	CcSEcCtD
Methylphenidate—Cardiac disorder—Epirubicin—prostate cancer	9.45e-05	0.000144	CcSEcCtD
Methylphenidate—Flushing—Epirubicin—prostate cancer	9.45e-05	0.000144	CcSEcCtD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—PRKACB—prostate cancer	9.45e-05	0.000601	CbGpPWpGaD
Methylphenidate—Rhinitis—Doxorubicin—prostate cancer	9.44e-05	0.000144	CcSEcCtD
Methylphenidate—Dyspepsia—Docetaxel—prostate cancer	9.44e-05	0.000144	CcSEcCtD
Methylphenidate—Haemorrhage—Doxorubicin—prostate cancer	9.42e-05	0.000144	CcSEcCtD
Methylphenidate—Insomnia—Capecitabine—prostate cancer	9.39e-05	0.000143	CcSEcCtD
Methylphenidate—SLC6A4—Circadian rythm related genes—EP300—prostate cancer	9.36e-05	0.000595	CbGpPWpGaD
Methylphenidate—CYP2D6—Metapathway biotransformation—CYP19A1—prostate cancer	9.36e-05	0.000595	CbGpPWpGaD
Methylphenidate—Pharyngitis—Doxorubicin—prostate cancer	9.35e-05	0.000142	CcSEcCtD
Methylphenidate—Paraesthesia—Capecitabine—prostate cancer	9.32e-05	0.000142	CcSEcCtD
Methylphenidate—Decreased appetite—Docetaxel—prostate cancer	9.32e-05	0.000142	CcSEcCtD
Methylphenidate—Urinary tract disorder—Doxorubicin—prostate cancer	9.3e-05	0.000142	CcSEcCtD
Methylphenidate—Gastrointestinal disorder—Docetaxel—prostate cancer	9.26e-05	0.000141	CcSEcCtD
Methylphenidate—Asthenia—Etoposide—prostate cancer	9.26e-05	0.000141	CcSEcCtD
Methylphenidate—Connective tissue disorder—Doxorubicin—prostate cancer	9.26e-05	0.000141	CcSEcCtD
Methylphenidate—Dyspnoea—Capecitabine—prostate cancer	9.26e-05	0.000141	CcSEcCtD
Methylphenidate—Oedema—Prednisone—prostate cancer	9.25e-05	0.000141	CcSEcCtD
Methylphenidate—Anaphylactic shock—Prednisone—prostate cancer	9.25e-05	0.000141	CcSEcCtD
Methylphenidate—Fatigue—Docetaxel—prostate cancer	9.25e-05	0.000141	CcSEcCtD
Methylphenidate—Angiopathy—Epirubicin—prostate cancer	9.24e-05	0.000141	CcSEcCtD
Methylphenidate—Urethral disorder—Doxorubicin—prostate cancer	9.23e-05	0.000141	CcSEcCtD
Methylphenidate—Nausea—Mitoxantrone—prostate cancer	9.21e-05	0.00014	CcSEcCtD
Methylphenidate—Immune system disorder—Epirubicin—prostate cancer	9.2e-05	0.00014	CcSEcCtD
Methylphenidate—Infection—Prednisone—prostate cancer	9.19e-05	0.00014	CcSEcCtD
Methylphenidate—Mediastinal disorder—Epirubicin—prostate cancer	9.18e-05	0.00014	CcSEcCtD
Methylphenidate—Pain—Docetaxel—prostate cancer	9.17e-05	0.00014	CcSEcCtD
Methylphenidate—Constipation—Docetaxel—prostate cancer	9.17e-05	0.00014	CcSEcCtD
Methylphenidate—CYP2D6—Biological oxidations—RXRA—prostate cancer	9.16e-05	0.000583	CbGpPWpGaD
Methylphenidate—Dyspepsia—Capecitabine—prostate cancer	9.14e-05	0.000139	CcSEcCtD
Methylphenidate—Chills—Epirubicin—prostate cancer	9.13e-05	0.000139	CcSEcCtD
Methylphenidate—Pruritus—Etoposide—prostate cancer	9.13e-05	0.000139	CcSEcCtD
Methylphenidate—Shock—Prednisone—prostate cancer	9.1e-05	0.000139	CcSEcCtD
Methylphenidate—Arrhythmia—Epirubicin—prostate cancer	9.09e-05	0.000139	CcSEcCtD
Methylphenidate—Visual impairment—Doxorubicin—prostate cancer	9.08e-05	0.000138	CcSEcCtD
Methylphenidate—Nervous system disorder—Prednisone—prostate cancer	9.07e-05	0.000138	CcSEcCtD
Methylphenidate—SLC6A2—NRF2 pathway—TGFB1—prostate cancer	9.04e-05	0.000575	CbGpPWpGaD
Methylphenidate—Tachycardia—Prednisone—prostate cancer	9.03e-05	0.000137	CcSEcCtD
Methylphenidate—Decreased appetite—Capecitabine—prostate cancer	9.03e-05	0.000137	CcSEcCtD
Methylphenidate—Alopecia—Epirubicin—prostate cancer	9e-05	0.000137	CcSEcCtD
Methylphenidate—Skin disorder—Prednisone—prostate cancer	8.98e-05	0.000137	CcSEcCtD
Methylphenidate—Gastrointestinal disorder—Capecitabine—prostate cancer	8.96e-05	0.000137	CcSEcCtD
Methylphenidate—Fatigue—Capecitabine—prostate cancer	8.95e-05	0.000136	CcSEcCtD
Methylphenidate—Hyperhidrosis—Prednisone—prostate cancer	8.94e-05	0.000136	CcSEcCtD
Methylphenidate—SLC6A3—Transmission across Chemical Synapses—MDM2—prostate cancer	8.93e-05	0.000568	CbGpPWpGaD
Methylphenidate—Mental disorder—Epirubicin—prostate cancer	8.92e-05	0.000136	CcSEcCtD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—NCOA2—prostate cancer	8.91e-05	0.000567	CbGpPWpGaD
Methylphenidate—Erythema multiforme—Doxorubicin—prostate cancer	8.91e-05	0.000136	CcSEcCtD
Methylphenidate—Constipation—Capecitabine—prostate cancer	8.88e-05	0.000135	CcSEcCtD
Methylphenidate—Pain—Capecitabine—prostate cancer	8.88e-05	0.000135	CcSEcCtD
Methylphenidate—Malnutrition—Epirubicin—prostate cancer	8.86e-05	0.000135	CcSEcCtD
Methylphenidate—Erythema—Epirubicin—prostate cancer	8.86e-05	0.000135	CcSEcCtD
Methylphenidate—Feeling abnormal—Docetaxel—prostate cancer	8.84e-05	0.000135	CcSEcCtD
Methylphenidate—Diarrhoea—Etoposide—prostate cancer	8.83e-05	0.000134	CcSEcCtD
Methylphenidate—CYP2D6—Biological oxidations—COMT—prostate cancer	8.82e-05	0.000561	CbGpPWpGaD
Methylphenidate—Anorexia—Prednisone—prostate cancer	8.82e-05	0.000134	CcSEcCtD
Methylphenidate—Eye disorder—Doxorubicin—prostate cancer	8.8e-05	0.000134	CcSEcCtD
Methylphenidate—CYP2D6—Biological oxidations—GSTP1—prostate cancer	8.78e-05	0.000559	CbGpPWpGaD
Methylphenidate—Gastrointestinal pain—Docetaxel—prostate cancer	8.77e-05	0.000134	CcSEcCtD
Methylphenidate—Cardiac disorder—Doxorubicin—prostate cancer	8.74e-05	0.000133	CcSEcCtD
Methylphenidate—Flushing—Doxorubicin—prostate cancer	8.74e-05	0.000133	CcSEcCtD
Methylphenidate—CYP2D6—Metapathway biotransformation—COMT—prostate cancer	8.7e-05	0.000554	CbGpPWpGaD
Methylphenidate—Tension—Epirubicin—prostate cancer	8.7e-05	0.000132	CcSEcCtD
Methylphenidate—CYP2D6—Metapathway biotransformation—GSTP1—prostate cancer	8.66e-05	0.000551	CbGpPWpGaD
Methylphenidate—Nervousness—Epirubicin—prostate cancer	8.61e-05	0.000131	CcSEcCtD
Methylphenidate—Back pain—Epirubicin—prostate cancer	8.57e-05	0.000131	CcSEcCtD
Methylphenidate—Feeling abnormal—Capecitabine—prostate cancer	8.56e-05	0.00013	CcSEcCtD
Methylphenidate—Angiopathy—Doxorubicin—prostate cancer	8.55e-05	0.00013	CcSEcCtD
Methylphenidate—Dizziness—Etoposide—prostate cancer	8.53e-05	0.00013	CcSEcCtD
Methylphenidate—Muscle spasms—Epirubicin—prostate cancer	8.52e-05	0.00013	CcSEcCtD
Methylphenidate—Immune system disorder—Doxorubicin—prostate cancer	8.51e-05	0.00013	CcSEcCtD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—SLC5A5—prostate cancer	8.5e-05	0.000541	CbGpPWpGaD
Methylphenidate—Gastrointestinal pain—Capecitabine—prostate cancer	8.49e-05	0.000129	CcSEcCtD
Methylphenidate—Mediastinal disorder—Doxorubicin—prostate cancer	8.49e-05	0.000129	CcSEcCtD
Methylphenidate—Abdominal pain—Docetaxel—prostate cancer	8.48e-05	0.000129	CcSEcCtD
Methylphenidate—Body temperature increased—Docetaxel—prostate cancer	8.48e-05	0.000129	CcSEcCtD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—NCOA1—prostate cancer	8.47e-05	0.000539	CbGpPWpGaD
Methylphenidate—Chills—Doxorubicin—prostate cancer	8.45e-05	0.000129	CcSEcCtD
Methylphenidate—Musculoskeletal discomfort—Prednisone—prostate cancer	8.43e-05	0.000128	CcSEcCtD
Methylphenidate—Arrhythmia—Doxorubicin—prostate cancer	8.41e-05	0.000128	CcSEcCtD
Methylphenidate—Insomnia—Prednisone—prostate cancer	8.36e-05	0.000127	CcSEcCtD
Methylphenidate—Vision blurred—Epirubicin—prostate cancer	8.35e-05	0.000127	CcSEcCtD
Methylphenidate—Alopecia—Doxorubicin—prostate cancer	8.32e-05	0.000127	CcSEcCtD
Methylphenidate—Paraesthesia—Prednisone—prostate cancer	8.3e-05	0.000127	CcSEcCtD
Methylphenidate—Mental disorder—Doxorubicin—prostate cancer	8.25e-05	0.000126	CcSEcCtD
Methylphenidate—Urticaria—Capecitabine—prostate cancer	8.25e-05	0.000126	CcSEcCtD
Methylphenidate—Ill-defined disorder—Epirubicin—prostate cancer	8.22e-05	0.000125	CcSEcCtD
Methylphenidate—Body temperature increased—Capecitabine—prostate cancer	8.21e-05	0.000125	CcSEcCtD
Methylphenidate—Abdominal pain—Capecitabine—prostate cancer	8.21e-05	0.000125	CcSEcCtD
Methylphenidate—Vomiting—Etoposide—prostate cancer	8.2e-05	0.000125	CcSEcCtD
Methylphenidate—Erythema—Doxorubicin—prostate cancer	8.2e-05	0.000125	CcSEcCtD
Methylphenidate—Malnutrition—Doxorubicin—prostate cancer	8.2e-05	0.000125	CcSEcCtD
Methylphenidate—Anaemia—Epirubicin—prostate cancer	8.19e-05	0.000125	CcSEcCtD
Methylphenidate—Agitation—Epirubicin—prostate cancer	8.14e-05	0.000124	CcSEcCtD
Methylphenidate—Dyspepsia—Prednisone—prostate cancer	8.14e-05	0.000124	CcSEcCtD
Methylphenidate—Rash—Etoposide—prostate cancer	8.14e-05	0.000124	CcSEcCtD
Methylphenidate—Dermatitis—Etoposide—prostate cancer	8.13e-05	0.000124	CcSEcCtD
Methylphenidate—Headache—Etoposide—prostate cancer	8.08e-05	0.000123	CcSEcCtD
Methylphenidate—CYP2D6—Biological oxidations—GSTM1—prostate cancer	8.07e-05	0.000513	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—RXRA—prostate cancer	8.06e-05	0.000513	CbGpPWpGaD
Methylphenidate—Tension—Doxorubicin—prostate cancer	8.05e-05	0.000123	CcSEcCtD
Methylphenidate—Decreased appetite—Prednisone—prostate cancer	8.04e-05	0.000122	CcSEcCtD
Methylphenidate—SLC6A3—NRF2 pathway—TGFB1—prostate cancer	8.01e-05	0.000509	CbGpPWpGaD
Methylphenidate—Malaise—Epirubicin—prostate cancer	7.99e-05	0.000122	CcSEcCtD
Methylphenidate—Fatigue—Prednisone—prostate cancer	7.97e-05	0.000121	CcSEcCtD
Methylphenidate—Nervousness—Doxorubicin—prostate cancer	7.96e-05	0.000121	CcSEcCtD
Methylphenidate—Vertigo—Epirubicin—prostate cancer	7.96e-05	0.000121	CcSEcCtD
Methylphenidate—CYP2D6—Metapathway biotransformation—GSTM1—prostate cancer	7.96e-05	0.000506	CbGpPWpGaD
Methylphenidate—Syncope—Epirubicin—prostate cancer	7.95e-05	0.000121	CcSEcCtD
Methylphenidate—Leukopenia—Epirubicin—prostate cancer	7.93e-05	0.000121	CcSEcCtD
Methylphenidate—Back pain—Doxorubicin—prostate cancer	7.93e-05	0.000121	CcSEcCtD
Methylphenidate—Constipation—Prednisone—prostate cancer	7.91e-05	0.00012	CcSEcCtD
Methylphenidate—Hypersensitivity—Docetaxel—prostate cancer	7.9e-05	0.00012	CcSEcCtD
Methylphenidate—Muscle spasms—Doxorubicin—prostate cancer	7.88e-05	0.00012	CcSEcCtD
Methylphenidate—Palpitations—Epirubicin—prostate cancer	7.83e-05	0.000119	CcSEcCtD
Methylphenidate—Loss of consciousness—Epirubicin—prostate cancer	7.79e-05	0.000119	CcSEcCtD
Methylphenidate—Cough—Epirubicin—prostate cancer	7.73e-05	0.000118	CcSEcCtD
Methylphenidate—Vision blurred—Doxorubicin—prostate cancer	7.73e-05	0.000118	CcSEcCtD
Methylphenidate—Asthenia—Docetaxel—prostate cancer	7.69e-05	0.000117	CcSEcCtD
Methylphenidate—Convulsion—Epirubicin—prostate cancer	7.68e-05	0.000117	CcSEcCtD
Methylphenidate—Nausea—Etoposide—prostate cancer	7.66e-05	0.000117	CcSEcCtD
Methylphenidate—Hypertension—Epirubicin—prostate cancer	7.65e-05	0.000117	CcSEcCtD
Methylphenidate—CYP2D6—Biological oxidations—CYP1A1—prostate cancer	7.65e-05	0.000487	CbGpPWpGaD
Methylphenidate—Hypersensitivity—Capecitabine—prostate cancer	7.65e-05	0.000117	CcSEcCtD
Methylphenidate—Feeling abnormal—Prednisone—prostate cancer	7.62e-05	0.000116	CcSEcCtD
Methylphenidate—Ill-defined disorder—Doxorubicin—prostate cancer	7.61e-05	0.000116	CcSEcCtD
Methylphenidate—Pruritus—Docetaxel—prostate cancer	7.59e-05	0.000116	CcSEcCtD
Methylphenidate—Anaemia—Doxorubicin—prostate cancer	7.58e-05	0.000115	CcSEcCtD
Methylphenidate—Gastrointestinal pain—Prednisone—prostate cancer	7.56e-05	0.000115	CcSEcCtD
Methylphenidate—CYP2D6—Metabolism—HAO1—prostate cancer	7.55e-05	0.00048	CbGpPWpGaD
Methylphenidate—Chest pain—Epirubicin—prostate cancer	7.54e-05	0.000115	CcSEcCtD
Methylphenidate—Arthralgia—Epirubicin—prostate cancer	7.54e-05	0.000115	CcSEcCtD
Methylphenidate—Myalgia—Epirubicin—prostate cancer	7.54e-05	0.000115	CcSEcCtD
Methylphenidate—CYP2D6—Metapathway biotransformation—CYP1A1—prostate cancer	7.54e-05	0.00048	CbGpPWpGaD
Methylphenidate—Agitation—Doxorubicin—prostate cancer	7.54e-05	0.000115	CcSEcCtD
Methylphenidate—Anxiety—Epirubicin—prostate cancer	7.52e-05	0.000115	CcSEcCtD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—IL6—prostate cancer	7.51e-05	0.000478	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—NCOA1—prostate cancer	7.51e-05	0.000478	CbGpPWpGaD
Methylphenidate—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	7.49e-05	0.000114	CcSEcCtD
Methylphenidate—Discomfort—Epirubicin—prostate cancer	7.45e-05	0.000114	CcSEcCtD
Methylphenidate—Asthenia—Capecitabine—prostate cancer	7.45e-05	0.000113	CcSEcCtD
Methylphenidate—Malaise—Doxorubicin—prostate cancer	7.39e-05	0.000113	CcSEcCtD
Methylphenidate—Dry mouth—Epirubicin—prostate cancer	7.38e-05	0.000112	CcSEcCtD
Methylphenidate—Vertigo—Doxorubicin—prostate cancer	7.37e-05	0.000112	CcSEcCtD
Methylphenidate—Syncope—Doxorubicin—prostate cancer	7.35e-05	0.000112	CcSEcCtD
Methylphenidate—Urticaria—Prednisone—prostate cancer	7.35e-05	0.000112	CcSEcCtD
Methylphenidate—Pruritus—Capecitabine—prostate cancer	7.35e-05	0.000112	CcSEcCtD
Methylphenidate—Leukopenia—Doxorubicin—prostate cancer	7.34e-05	0.000112	CcSEcCtD
Methylphenidate—Diarrhoea—Docetaxel—prostate cancer	7.34e-05	0.000112	CcSEcCtD
Methylphenidate—Abdominal pain—Prednisone—prostate cancer	7.31e-05	0.000111	CcSEcCtD
Methylphenidate—Body temperature increased—Prednisone—prostate cancer	7.31e-05	0.000111	CcSEcCtD
Methylphenidate—Confusional state—Epirubicin—prostate cancer	7.29e-05	0.000111	CcSEcCtD
Methylphenidate—Palpitations—Doxorubicin—prostate cancer	7.25e-05	0.00011	CcSEcCtD
Methylphenidate—Oedema—Epirubicin—prostate cancer	7.23e-05	0.00011	CcSEcCtD
Methylphenidate—Anaphylactic shock—Epirubicin—prostate cancer	7.23e-05	0.00011	CcSEcCtD
Methylphenidate—Loss of consciousness—Doxorubicin—prostate cancer	7.21e-05	0.00011	CcSEcCtD
Methylphenidate—Infection—Epirubicin—prostate cancer	7.19e-05	0.000109	CcSEcCtD
Methylphenidate—Cough—Doxorubicin—prostate cancer	7.16e-05	0.000109	CcSEcCtD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—RXRA—prostate cancer	7.14e-05	0.000454	CbGpPWpGaD
Methylphenidate—Shock—Epirubicin—prostate cancer	7.12e-05	0.000108	CcSEcCtD
Methylphenidate—Convulsion—Doxorubicin—prostate cancer	7.1e-05	0.000108	CcSEcCtD
Methylphenidate—Diarrhoea—Capecitabine—prostate cancer	7.1e-05	0.000108	CcSEcCtD
Methylphenidate—Nervous system disorder—Epirubicin—prostate cancer	7.09e-05	0.000108	CcSEcCtD
Methylphenidate—Dizziness—Docetaxel—prostate cancer	7.09e-05	0.000108	CcSEcCtD
Methylphenidate—Thrombocytopenia—Epirubicin—prostate cancer	7.08e-05	0.000108	CcSEcCtD
Methylphenidate—Hypertension—Doxorubicin—prostate cancer	7.08e-05	0.000108	CcSEcCtD
Methylphenidate—Tachycardia—Epirubicin—prostate cancer	7.06e-05	0.000108	CcSEcCtD
Methylphenidate—Skin disorder—Epirubicin—prostate cancer	7.03e-05	0.000107	CcSEcCtD
Methylphenidate—Hyperhidrosis—Epirubicin—prostate cancer	6.99e-05	0.000107	CcSEcCtD
Methylphenidate—Arthralgia—Doxorubicin—prostate cancer	6.98e-05	0.000106	CcSEcCtD
Methylphenidate—Chest pain—Doxorubicin—prostate cancer	6.98e-05	0.000106	CcSEcCtD
Methylphenidate—Myalgia—Doxorubicin—prostate cancer	6.98e-05	0.000106	CcSEcCtD
Methylphenidate—Anxiety—Doxorubicin—prostate cancer	6.96e-05	0.000106	CcSEcCtD
Methylphenidate—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	6.93e-05	0.000106	CcSEcCtD
Methylphenidate—Discomfort—Doxorubicin—prostate cancer	6.9e-05	0.000105	CcSEcCtD
Methylphenidate—Anorexia—Epirubicin—prostate cancer	6.89e-05	0.000105	CcSEcCtD
Methylphenidate—Dizziness—Capecitabine—prostate cancer	6.87e-05	0.000105	CcSEcCtD
Methylphenidate—SLC6A3—Neuronal System—MDM2—prostate cancer	6.84e-05	0.000435	CbGpPWpGaD
Methylphenidate—Dry mouth—Doxorubicin—prostate cancer	6.83e-05	0.000104	CcSEcCtD
Methylphenidate—Vomiting—Docetaxel—prostate cancer	6.82e-05	0.000104	CcSEcCtD
Methylphenidate—Hypersensitivity—Prednisone—prostate cancer	6.81e-05	0.000104	CcSEcCtD
Methylphenidate—Rash—Docetaxel—prostate cancer	6.76e-05	0.000103	CcSEcCtD
Methylphenidate—Dermatitis—Docetaxel—prostate cancer	6.75e-05	0.000103	CcSEcCtD
Methylphenidate—Confusional state—Doxorubicin—prostate cancer	6.75e-05	0.000103	CcSEcCtD
Methylphenidate—Headache—Docetaxel—prostate cancer	6.72e-05	0.000102	CcSEcCtD
Methylphenidate—SLC6A4—Circadian rythm related genes—TP53—prostate cancer	6.7e-05	0.000426	CbGpPWpGaD
Methylphenidate—Anaphylactic shock—Doxorubicin—prostate cancer	6.69e-05	0.000102	CcSEcCtD
Methylphenidate—Oedema—Doxorubicin—prostate cancer	6.69e-05	0.000102	CcSEcCtD
Methylphenidate—Infection—Doxorubicin—prostate cancer	6.65e-05	0.000101	CcSEcCtD
Methylphenidate—Asthenia—Prednisone—prostate cancer	6.64e-05	0.000101	CcSEcCtD
Methylphenidate—Vomiting—Capecitabine—prostate cancer	6.6e-05	0.000101	CcSEcCtD
Methylphenidate—Musculoskeletal discomfort—Epirubicin—prostate cancer	6.59e-05	0.0001	CcSEcCtD
Methylphenidate—Shock—Doxorubicin—prostate cancer	6.58e-05	0.0001	CcSEcCtD
Methylphenidate—Nervous system disorder—Doxorubicin—prostate cancer	6.56e-05	0.0001	CcSEcCtD
Methylphenidate—Thrombocytopenia—Doxorubicin—prostate cancer	6.55e-05	9.98e-05	CcSEcCtD
Methylphenidate—Rash—Capecitabine—prostate cancer	6.55e-05	9.97e-05	CcSEcCtD
Methylphenidate—Pruritus—Prednisone—prostate cancer	6.54e-05	9.97e-05	CcSEcCtD
Methylphenidate—Insomnia—Epirubicin—prostate cancer	6.54e-05	9.97e-05	CcSEcCtD
Methylphenidate—Dermatitis—Capecitabine—prostate cancer	6.54e-05	9.96e-05	CcSEcCtD
Methylphenidate—Tachycardia—Doxorubicin—prostate cancer	6.53e-05	9.95e-05	CcSEcCtD
Methylphenidate—Headache—Capecitabine—prostate cancer	6.5e-05	9.91e-05	CcSEcCtD
Methylphenidate—Skin disorder—Doxorubicin—prostate cancer	6.5e-05	9.9e-05	CcSEcCtD
Methylphenidate—Paraesthesia—Epirubicin—prostate cancer	6.49e-05	9.89e-05	CcSEcCtD
Methylphenidate—Hyperhidrosis—Doxorubicin—prostate cancer	6.47e-05	9.86e-05	CcSEcCtD
Methylphenidate—Dyspnoea—Epirubicin—prostate cancer	6.45e-05	9.82e-05	CcSEcCtD
Methylphenidate—Somnolence—Epirubicin—prostate cancer	6.43e-05	9.8e-05	CcSEcCtD
Methylphenidate—Anorexia—Doxorubicin—prostate cancer	6.38e-05	9.72e-05	CcSEcCtD
Methylphenidate—Nausea—Docetaxel—prostate cancer	6.37e-05	9.7e-05	CcSEcCtD
Methylphenidate—Dyspepsia—Epirubicin—prostate cancer	6.37e-05	9.7e-05	CcSEcCtD
Methylphenidate—Diarrhoea—Prednisone—prostate cancer	6.33e-05	9.64e-05	CcSEcCtD
Methylphenidate—Decreased appetite—Epirubicin—prostate cancer	6.29e-05	9.58e-05	CcSEcCtD
Methylphenidate—Gastrointestinal disorder—Epirubicin—prostate cancer	6.24e-05	9.51e-05	CcSEcCtD
Methylphenidate—Fatigue—Epirubicin—prostate cancer	6.24e-05	9.5e-05	CcSEcCtD
Methylphenidate—Constipation—Epirubicin—prostate cancer	6.19e-05	9.42e-05	CcSEcCtD
Methylphenidate—Pain—Epirubicin—prostate cancer	6.19e-05	9.42e-05	CcSEcCtD
Methylphenidate—Nausea—Capecitabine—prostate cancer	6.17e-05	9.39e-05	CcSEcCtD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—PPARA—prostate cancer	6.16e-05	0.000392	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—PSAT1—prostate cancer	6.15e-05	0.000392	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—GRHL1—prostate cancer	6.15e-05	0.000392	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—TST—prostate cancer	6.15e-05	0.000392	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—ADI1—prostate cancer	6.15e-05	0.000392	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—CSAD—prostate cancer	6.15e-05	0.000392	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—CBR1—prostate cancer	6.15e-05	0.000392	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—IL6—prostate cancer	6.13e-05	0.00039	CbGpPWpGaD
Methylphenidate—Dizziness—Prednisone—prostate cancer	6.12e-05	9.32e-05	CcSEcCtD
Methylphenidate—Musculoskeletal discomfort—Doxorubicin—prostate cancer	6.1e-05	9.29e-05	CcSEcCtD
Methylphenidate—Insomnia—Doxorubicin—prostate cancer	6.05e-05	9.22e-05	CcSEcCtD
Methylphenidate—Paraesthesia—Doxorubicin—prostate cancer	6.01e-05	9.15e-05	CcSEcCtD
Methylphenidate—Dyspnoea—Doxorubicin—prostate cancer	5.97e-05	9.09e-05	CcSEcCtD
Methylphenidate—Feeling abnormal—Epirubicin—prostate cancer	5.96e-05	9.08e-05	CcSEcCtD
Methylphenidate—Somnolence—Doxorubicin—prostate cancer	5.95e-05	9.06e-05	CcSEcCtD
Methylphenidate—Gastrointestinal pain—Epirubicin—prostate cancer	5.91e-05	9.01e-05	CcSEcCtD
Methylphenidate—Dyspepsia—Doxorubicin—prostate cancer	5.89e-05	8.97e-05	CcSEcCtD
Methylphenidate—Vomiting—Prednisone—prostate cancer	5.88e-05	8.96e-05	CcSEcCtD
Methylphenidate—Rash—Prednisone—prostate cancer	5.83e-05	8.88e-05	CcSEcCtD
Methylphenidate—Dermatitis—Prednisone—prostate cancer	5.83e-05	8.87e-05	CcSEcCtD
Methylphenidate—Decreased appetite—Doxorubicin—prostate cancer	5.82e-05	8.86e-05	CcSEcCtD
Methylphenidate—Headache—Prednisone—prostate cancer	5.79e-05	8.83e-05	CcSEcCtD
Methylphenidate—Gastrointestinal disorder—Doxorubicin—prostate cancer	5.78e-05	8.8e-05	CcSEcCtD
Methylphenidate—Fatigue—Doxorubicin—prostate cancer	5.77e-05	8.79e-05	CcSEcCtD
Methylphenidate—Urticaria—Epirubicin—prostate cancer	5.75e-05	8.75e-05	CcSEcCtD
Methylphenidate—Pain—Doxorubicin—prostate cancer	5.72e-05	8.72e-05	CcSEcCtD
Methylphenidate—Constipation—Doxorubicin—prostate cancer	5.72e-05	8.72e-05	CcSEcCtD
Methylphenidate—CYP2D6—Metabolism—GRHPR—prostate cancer	5.72e-05	0.000364	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—CKMT2—prostate cancer	5.72e-05	0.000364	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—UGT2B17—prostate cancer	5.72e-05	0.000364	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—UGT2B15—prostate cancer	5.72e-05	0.000364	CbGpPWpGaD
Methylphenidate—Abdominal pain—Epirubicin—prostate cancer	5.72e-05	8.71e-05	CcSEcCtD
Methylphenidate—Body temperature increased—Epirubicin—prostate cancer	5.72e-05	8.71e-05	CcSEcCtD
Methylphenidate—Feeling abnormal—Doxorubicin—prostate cancer	5.51e-05	8.4e-05	CcSEcCtD
Methylphenidate—Nausea—Prednisone—prostate cancer	5.49e-05	8.37e-05	CcSEcCtD
Methylphenidate—Gastrointestinal pain—Doxorubicin—prostate cancer	5.47e-05	8.34e-05	CcSEcCtD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—PPARA—prostate cancer	5.45e-05	0.000347	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—PGAM2—prostate cancer	5.38e-05	0.000342	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—RFK—prostate cancer	5.38e-05	0.000342	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—NAGLU—prostate cancer	5.38e-05	0.000342	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—SULT2B1—prostate cancer	5.38e-05	0.000342	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—MBTPS1—prostate cancer	5.38e-05	0.000342	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—AOX1—prostate cancer	5.38e-05	0.000342	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—GSTM3—prostate cancer	5.38e-05	0.000342	CbGpPWpGaD
Methylphenidate—Hypersensitivity—Epirubicin—prostate cancer	5.33e-05	8.12e-05	CcSEcCtD
Methylphenidate—Urticaria—Doxorubicin—prostate cancer	5.32e-05	8.1e-05	CcSEcCtD
Methylphenidate—Body temperature increased—Doxorubicin—prostate cancer	5.29e-05	8.06e-05	CcSEcCtD
Methylphenidate—Abdominal pain—Doxorubicin—prostate cancer	5.29e-05	8.06e-05	CcSEcCtD
Methylphenidate—Asthenia—Epirubicin—prostate cancer	5.19e-05	7.91e-05	CcSEcCtD
Methylphenidate—Pruritus—Epirubicin—prostate cancer	5.12e-05	7.8e-05	CcSEcCtD
Methylphenidate—CYP2D6—Metabolism—CYP3A43—prostate cancer	5.1e-05	0.000324	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—SRD5A2—prostate cancer	5.1e-05	0.000324	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—DEGS1—prostate cancer	5.1e-05	0.000324	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—NAT1—prostate cancer	5.1e-05	0.000324	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—AMACR—prostate cancer	5.1e-05	0.000324	CbGpPWpGaD
Methylphenidate—Diarrhoea—Epirubicin—prostate cancer	4.95e-05	7.54e-05	CcSEcCtD
Methylphenidate—Hypersensitivity—Doxorubicin—prostate cancer	4.93e-05	7.51e-05	CcSEcCtD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—CREBBP—prostate cancer	4.89e-05	0.000311	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—HSD17B1—prostate cancer	4.86e-05	0.000309	CbGpPWpGaD
Methylphenidate—Asthenia—Doxorubicin—prostate cancer	4.8e-05	7.31e-05	CcSEcCtD
Methylphenidate—Dizziness—Epirubicin—prostate cancer	4.78e-05	7.29e-05	CcSEcCtD
Methylphenidate—Pruritus—Doxorubicin—prostate cancer	4.73e-05	7.21e-05	CcSEcCtD
Methylphenidate—Vomiting—Epirubicin—prostate cancer	4.6e-05	7.01e-05	CcSEcCtD
Methylphenidate—Diarrhoea—Doxorubicin—prostate cancer	4.58e-05	6.98e-05	CcSEcCtD
Methylphenidate—Rash—Epirubicin—prostate cancer	4.56e-05	6.95e-05	CcSEcCtD
Methylphenidate—Dermatitis—Epirubicin—prostate cancer	4.56e-05	6.94e-05	CcSEcCtD
Methylphenidate—Headache—Epirubicin—prostate cancer	4.53e-05	6.9e-05	CcSEcCtD
Methylphenidate—Dizziness—Doxorubicin—prostate cancer	4.43e-05	6.74e-05	CcSEcCtD
Methylphenidate—CYP2D6—Metabolism—B4GALT4—prostate cancer	4.34e-05	0.000276	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—HPGD—prostate cancer	4.34e-05	0.000276	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—CREBBP—prostate cancer	4.33e-05	0.000275	CbGpPWpGaD
Methylphenidate—Nausea—Epirubicin—prostate cancer	4.3e-05	6.54e-05	CcSEcCtD
Methylphenidate—Vomiting—Doxorubicin—prostate cancer	4.26e-05	6.48e-05	CcSEcCtD
Methylphenidate—Rash—Doxorubicin—prostate cancer	4.22e-05	6.43e-05	CcSEcCtD
Methylphenidate—Dermatitis—Doxorubicin—prostate cancer	4.22e-05	6.42e-05	CcSEcCtD
Methylphenidate—Headache—Doxorubicin—prostate cancer	4.19e-05	6.39e-05	CcSEcCtD
Methylphenidate—CYP2D6—Metabolism—TNFRSF21—prostate cancer	4.08e-05	0.000259	CbGpPWpGaD
Methylphenidate—Nausea—Doxorubicin—prostate cancer	3.98e-05	6.06e-05	CcSEcCtD
Methylphenidate—CYP2D6—Metabolism—MTAP—prostate cancer	3.97e-05	0.000252	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—CYP7B1—prostate cancer	3.97e-05	0.000252	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—SRD5A1—prostate cancer	3.86e-05	0.000246	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—SULT1E1—prostate cancer	3.86e-05	0.000246	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—ACSL4—prostate cancer	3.69e-05	0.000235	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—HSD17B3—prostate cancer	3.69e-05	0.000235	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—UMPS—prostate cancer	3.53e-05	0.000225	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—ARG2—prostate cancer	3.53e-05	0.000225	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—PHGDH—prostate cancer	3.53e-05	0.000225	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—LDHB—prostate cancer	3.47e-05	0.000221	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—CYP3A5—prostate cancer	3.4e-05	0.000216	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—GSTA3—prostate cancer	3.29e-05	0.000209	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—UCP3—prostate cancer	3.29e-05	0.000209	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—TCN2—prostate cancer	3.29e-05	0.000209	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—PDHA1—prostate cancer	3.29e-05	0.000209	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—HSD3B1—prostate cancer	3.13e-05	0.000199	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—SLC22A3—prostate cancer	3.13e-05	0.000199	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—GSTA4—prostate cancer	3.01e-05	0.000191	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—TBXAS1—prostate cancer	3.01e-05	0.000191	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—GSTA2—prostate cancer	2.93e-05	0.000186	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—SULT1A1—prostate cancer	2.89e-05	0.000184	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—ABCG5—prostate cancer	2.89e-05	0.000184	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—GSTA1—prostate cancer	2.83e-05	0.00018	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—HSD3B2—prostate cancer	2.79e-05	0.000178	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—GSTO1—prostate cancer	2.79e-05	0.000178	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—NAT2—prostate cancer	2.79e-05	0.000178	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—PLCB2—prostate cancer	2.68e-05	0.00017	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—LRP2—prostate cancer	2.68e-05	0.00017	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—CYP2C18—prostate cancer	2.68e-05	0.00017	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—P4HB—prostate cancer	2.63e-05	0.000167	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—SLC22A1—prostate cancer	2.56e-05	0.000163	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—SULT2A1—prostate cancer	2.49e-05	0.000158	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—MED12—prostate cancer	2.45e-05	0.000156	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—GNG5—prostate cancer	2.43e-05	0.000155	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—NCOA3—prostate cancer	2.34e-05	0.000149	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—HPGDS—prostate cancer	2.23e-05	0.000142	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—CYP2C19—prostate cancer	2.22e-05	0.000141	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—ACHE—prostate cancer	2.17e-05	0.000138	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—GSTT1—prostate cancer	2.17e-05	0.000138	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—CYP2A6—prostate cancer	2.14e-05	0.000136	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—AKR1C3—prostate cancer	2.08e-05	0.000133	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—PRKACB—prostate cancer	2.07e-05	0.000132	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—CYP17A1—prostate cancer	2.05e-05	0.00013	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—NCOA2—prostate cancer	1.95e-05	0.000124	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—SLC5A5—prostate cancer	1.86e-05	0.000119	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—CYP2E1—prostate cancer	1.82e-05	0.000116	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—NQO1—prostate cancer	1.8e-05	0.000115	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—TH—prostate cancer	1.77e-05	0.000113	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—CYP3A4—prostate cancer	1.76e-05	0.000112	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—CYP1B1—prostate cancer	1.73e-05	0.00011	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—GGT1—prostate cancer	1.67e-05	0.000106	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—NCOA1—prostate cancer	1.65e-05	0.000105	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—CYP19A1—prostate cancer	1.62e-05	0.000103	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—RXRA—prostate cancer	1.57e-05	9.96e-05	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—COMT—prostate cancer	1.51e-05	9.6e-05	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—GSTP1—prostate cancer	1.5e-05	9.55e-05	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—ITPR1—prostate cancer	1.48e-05	9.4e-05	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—TYMS—prostate cancer	1.4e-05	8.88e-05	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—GSTM1—prostate cancer	1.38e-05	8.78e-05	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—LPL—prostate cancer	1.35e-05	8.62e-05	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—CYP1A1—prostate cancer	1.31e-05	8.32e-05	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—ERCC2—prostate cancer	1.3e-05	8.25e-05	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—MTHFR—prostate cancer	1.22e-05	7.76e-05	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—PPARA—prostate cancer	1.2e-05	7.61e-05	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—CAV1—prostate cancer	1.12e-05	7.16e-05	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—PIK3CG—prostate cancer	1.02e-05	6.52e-05	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—INS—prostate cancer	9.7e-06	6.17e-05	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—CREBBP—prostate cancer	9.5e-06	6.04e-05	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—PIK3CD—prostate cancer	9.01e-06	5.73e-05	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—NOS3—prostate cancer	8.51e-06	5.41e-05	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—PIK3CB—prostate cancer	7.85e-06	5e-05	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—PTGS2—prostate cancer	7.78e-06	4.95e-05	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—PTEN—prostate cancer	6.78e-06	4.32e-05	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—EP300—prostate cancer	6.47e-06	4.12e-05	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—PIK3CA—prostate cancer	4.79e-06	3.05e-05	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—AKT1—prostate cancer	3.91e-06	2.49e-05	CbGpPWpGaD
